Venus Remedies’ participation in the UNGC further validates its longstanding commitment to responsible healthcare innovation, ethical governance, and environmental stewardship. The company has implemented a comprehensive Environmental, Social and Governance (ESG) strategy across its international operations. In line with its climate accountability goals, it has obtained ISO 14064-1 certification for greenhouse gas emissions reporting, ensuring transparency in environmental performance and carbon management.

“At Venus Remedies, we believe in advancing science with a strong sense of responsibility,” said Ms. Aditi K. Chaudhary, President, International Business, Venus Remedies Ltd. “Our decision to join the United Nations Global Compact is a natural extension of our core values, where access, ethics, and excellence converge. This milestone not only enhances our global standing but also reaffirms our commitment to driving meaningful change. We view this as a deep responsibility to our global partners, the healthcare systems we support, and the shared future of our planet.”

As a UNGC participant, Venus Remedies will publish an annual Communication on Progress (CoP) to share updates on its sustainability performance and adherence to the Compact’s principles. This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery.

Further strengthening its role in public health, Venus Remedies has been a long-standing supplier of WHO-prequalified pharmaceuticals to international health agencies. In recent years, the company has secured key supply contracts with UNICEF for the essential antibiotic ceftriaxone, and with the Pan American Health Organization (PAHO) for critical oncology medications. These partnerships enhance the company’s impact in delivering vital medicines to underserved populations across Latin America, Africa, and Asia.

Aligned with its commitment to SDG 3 and its ESG-led innovation roadmap, Venus Remedies has made antimicrobial resistance (AMR) a cornerstone of its R&D agenda. The company recognizes AMR not only as a scientific challenge, but as a global sustainability issue—impacting health systems, food security, and environmental resilience. Its continued investment in this area reflects the holistic approach to sustainable global health that the UNGC promotes.

In the area of AMR, Venus Remedies continues to innovate through its critical care pipeline. The company’s novel polymyxin B formulation, VRP-034, has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration under the GAIN (Generating Antibiotic Incentives Now) Act. This designation provides fast-track regulatory review and five additional years of market exclusivity post-approval, accelerating the delivery of next-generation antibiotics for drug-resistant infections.

Beyond product innovation, the company plays a key role in advancing AMR surveillance and global policy development. Its initiatives such as GASAR (Global Antimicrobial Surveillance and Resistance) help generate essential data on resistance patterns, while the PLEA Trust supports antibiotic stewardship through education and responsible use. Venus Remedies is also an active member of the AMR Industry Alliance, and contributes to cross-border collaboration on AMR strategy via the India AMR Innovation Hub and the Vivli AMR Register—initiatives that strengthen both public policy and clinical practice.

The company’s commitment to quality is reflected in its global manufacturing credentials. Venus Remedies holds Good Manufacturing Practice (GMP) approvals from several leading authorities, including EU-GMP (INFARMED), PIC/S members such as Malaysia and Ukraine, SAHPRA, UNICEF, TGA, INVIMA, and WHO-GMP. These are complemented by internationally recognized ISO certifications in quality management (ISO 9001), environmental management (ISO 14001), and occupational health and safety (ISO 45001), demonstrating its adherence to stringent global standards across facilities.

The post Venus Remedies Joins United Nations Global Compact, Reinforcing Commitment to Sustainable Global Healthcare appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

In this leadership role, Ms. Chaudhary will drive the company’s corporate social responsibility (CSR) agenda, focusing on healthcare access, educational advancement, and inclusive community development. Her appointment marks a significant step in strengthening the Foundation’s impact-driven initiatives aligned with Venus Remedies’ core values of equity, empowerment and environmental stewardship.

“We are delighted to welcome Ms. Ekta as Chairperson of Venus Foundation. Her vision, dedication, and global perspective make her uniquely positioned to lead our mission of creating meaningful and sustainable social change. I am confident her leadership will accelerate our efforts in areas such as women’s empowerment and healthcare equity,” said Mr. Pawan Chaudhary, Chairman and Managing Director, Venus Remedies Ltd.

The appointment reflects Venus Remedies’ commitment to evolving its CSR framework under future-ready leadership that blends scientific understanding with a passion for community welfare.

“Joining Venus Foundation is a unique opportunity to work alongside a purpose-driven team committed to operational excellence and social progress. I look forward to advancing the company’s CSR footprint by fostering a culture of inclusive growth. Together, we aim to build enduring partnerships and programs that empower individuals to lead change in their communities,” said Ms. Ekta S. Chaudhary, Chairperson, Venus Foundation.

A microbiologist by qualification, Ms. Chaudhary holds a degree from the University of Nottingham, a leading Russell Group institution in the UK. A passionate advocate for environmental action, she played a key role in launching Earthfest—London’s first large-scale sustainability festival—bringing together change makers, innovators, and thought leaders to raise awareness about climate action and responsible living. With early experience in the biotech and AI space in London, she is now channeling her global exposure and scientific perspective into purpose-driven work, marking the beginning of her journey in corporate social responsibility and community impact.

Since its inception, Venus Remedies has remained steadfast in its commitment to making a meaningful difference in the society through its initiatives. The company views education as a fundamental pillar of societal progress and has made consistent investments in the upliftment and modernization of government schools in Panchkula, creating more conducive and empowering learning environments for students. With the formal establishment of the Venus Foundation, the company seeks to further institutionalize its CSR outreach and deepen community partnerships, enabling lasting and scalable impact across key development areas.

The post Venus Remedies appoints Ekta S. Chaudhary as Chairperson of Venus Foundation to spearhead its CSR initiatives  appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

AdjuTec Pharma has developed novel inhibitor technologies that selectively destroy antibiotic resistance mechanisms in multidrug-resistant bacteria, thereby restoring the effectiveness of commercially available antibiotics. APC-148 is the lead program, that is presently in phase 1 clinical trials. As a frontrunner in antimicrobial resistance (AMR) research, Venus Remedies Limited will leverage its advanced R&D capabilities to assess APC-148’s potential in restoring the effectiveness of antibiotics against multidrug-resistant bacterial strains.

As part of this engagement, Venus Remedies Limited will test APC-148 in combination with various antibiotics against its extensive library of clinical isolates collected through the GASAR study. The study forms part of Venus Remedies’ broader commitment to combating AMR and contributing to the UN’s ‘One Health’ objective.

AdjuTec Pharma and Venus Remedies Limited share a joint mission to address the global health threat against AMR. AMR directly causes 1.3 million global deaths annually and is projected to cause 39 million accumulated global deaths by 2050. If left unchecked, AMR could surpass cancer as the leading cause of mortality.

In India, the situation is especially critical, with AMR being endemic and associated with over 300,000 deaths in 2019 alone, including among newborns. APC-148 has the potential to significantly restore the effectiveness of antibiotics against resistant bacterial strains that are increasingly burdening the Indian healthcare system.

AdjuTec Pharma AS, CEO, Jethro Holter said: “We are delighted to collaborate with Venus Remedies, a renowned Indian Company, with a share purpose and commitment to develop more effective antibiotics to combat the escalating global AMR crisis. This agreement perfectly aligns with our strategy to collaborate with leading and international pharmaceutical partners to address the most clinically challenging resistant pathogens through our groundbreaking technology.”

Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre said: “We are pleased to collaborate with AdjuTec Pharma on the preclinical evaluation of APC-148. This research engagement allows us to contribute our expertise in AMR toward advancing scientific understanding of novel solutions in this space. Our collaboration reflects a shared commitment to addressing the global AMR challenge through rigorous, innovation-driven research.”

The post AdjuTec Pharma and Venus Remedies Limited Initiate Research Collaboration to Evaluate APC-148 Against Antimicrobial Resistance (AMR) appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

·         The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations

·         With its debut registration of Sugammadex in Philippines, Venus Remedies strengthens its foothold in the ASEAN market

Bengaluru, March 04, 2025: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian manufacturer of injectable drugs, has received its first ever global marketing authorization for Sugammadex from the Philippines. This approval marks a major step in the company’s expansion into complex generics, reinforcing its commitment to high-value, technology-intensive formulations and expanding its foothold in the ASEAN market.

Sugammadex is a selective relaxant-binding agent (SRBA) used for the rapid reversal of neuromuscular blockade induced by rocuronium and vecuronium—two commonly used muscle relaxants in anesthesia. Unlike traditional agents, Sugammadex directly encapsulates and inactivates these drugs, offering a faster, safer, and more predictable recovery from anesthesia, reducing the risk of post-operative respiratory complications.

The global Sugammadex market, valued at approximately 1.53 billion in 2023, is projected to grow at a CAGR of 8.5%, reaching USD 2.89 billion by 2031.

Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre shared, “There is a growing demand for advanced surgical care and high-growth therapeutic segments in the Philippines which makes this approval particularly relevant. Venus Remedies holds marketing authorizations for several crucial drugs in the Philippines. Sugammadex represents our entry into high-barrier-to-entry complex generics, and we are committed to ensuring equitable access to such advanced medicines globally”.

Overall, the pharmaceutical market in the ASEAN region is projected to grow at a CAGR of 4.83% from 2025 to 2029. With its state-of-the-art manufacturing facilities, Venus Remedies is poised to capture a significant share in the Philippines and the wider ASEAN region.

“As a company committed to affordable access to cutting-edge medicines, our expansion into complex injectables and critical care drugs aligns with our long-term vision. The approval of Sugammadex is part of a broader strategy to penetrate both regulated and emerging markets, reinforcing our position in the high-growth ASEAN region”, said Mrs. Aditi Chaudhary, President, International Business, Venus Remedies.

The post Venus Remedies Secures Its First International Market Authorization for Sugammadex from the Philippines appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

Bengaluru, March 18, 2024: Venus Remedies, one of India’s leading exporters of generic medicines in critical care segments, has further expanded the reach of its oncology drugs in the Asia Commonwealth of Independent States (CIS) region with marketing authorisations from Ukraine for three cancer drugs, including paclitaxel, oxaliplatin and irinotecan.

With revenues projected to grow from US $607 million in 2022 to US $650.90 million by the end of this year, the Ukrainian pharmaceutical market has been witnessing steady growth. Venus Remedies’ emphasis on securing marketing approvals across the globe reflects its commitment to addressing the rising demand for high-quality healthcare solutions.

Having a presence in the Ukrainian market for more than two decades, Venus Remedies has 57 product registrations in Ukraine. Its total volume of exports to Ukraine stands at $2.20 million. By strengthening its product portfolio in Ukraine, the company aims to increase this figure by 20 per cent in the next one year.

Describing these marketing authorisations as a major stride in the company’s global consolidation, Saransh Chaudhary, President, Global Critical Care, Venus Remedies, said, “These marketing approvals mark a significant milestone in our global expansion strategy. We are looking forward to introducing the entire range of our oncology products in Ukraine in due course, thereby contributing to the advancement of healthcare and making a positive impact on people’s lives.”

Aditi K. Chaudhary, President, International Business, Venus Remedies, said these marketing approvals from Ukraine mark a significant milestone for the company as it continues to expand its global reach. “This achievement has further strengthened our position in the international pharmaceutical market. It also exemplifies our dedication to advancing healthcare solutions for diverse populations.”

Venus Remedies is awaiting approval from Ukraine on another 10 applications for marketing authorisations. With a population of 46.6 million, Ukraine is one of the largest countries in Europe, thus making it a potentially lucrative pharma market.

While Venus Remedies is the fourth largest exporter of chemotherapy drug paclitaxel from India, it is the sixth largest Indian exporter of oxaliplatin, another chemotherapy medication, and irinotecan, an antineoplastic agent. India exports paclitaxel, which is effective against advanced cancers, to 96 countries, oxaliplatin to 77 countries and irinotecan to 61 countries. The markets where Venus Remedies has been exporting these drugs include  Germany, Saudi Arabia, Malaysia, Indonesia, Philippines, Colombia, Venezuela, Morocco, Thailand, Botswana, Myanmar, Guyana, Tanzania, Kenya,  Zimbabwe, Pakistan, Mozambique, Senegal and Guatemala.

The company has secured the marketing approvals from Ukraine for paclitaxel in concentrations of 100mg/16.7ml, 260mg/43.3ml, 300mg/50ml, and 30mg/5ml; oxaliplatin in concentrations of 50mg/10ml and 100mg/20ml; and irinotecan in concentrations of 100mg/5ml and 40mg/2ml.

The post Venus Remedies secures regulatory approvals for three key oncology drugs in Ukraine appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

• • This expansion brings to the forefront a diverse range of products tailored to meet a spectrum of healthcare and wellness needs, including pain relief, mental well-being, restful sleep and detoxification

Mumbai, December 21, 2023: Venus Remedies Limited, a pioneer in pharmaceutical R&D, today unveiled a significant transformation of its consumer healthcare division, R3SET. This strategic pivot marks R3SET’s foray into the wellness arena, coupled with the expansion of its pain management portfolio, showcasing the company’s holistic approach to wellness solutions.

According to recent data from Euromonitor, the Indian Consumer Healthcare market was valued at Rs 42,392 crore in 2023 and is projected to grow by a 4-5% CAGR till 2028.

“R3SET’s entry into the wellness domain is not just an expansion; it’s a reflection of our ethos that wellness should be an intrinsic part of everyday life. Our products and brand identity are designed to nurture wellness as a daily ritual, seamlessly fitting into the consumer’s lifestyle,” stated Mr. Saransh Chaudhary, President, Consumer Healthcare, Venus Remedies Limited. “This strategic move is a testament to our commitment to making wellness an accessible, everyday experience for our consumers,” he added.

The launch of R3SET Detox Candies, crafted with a blend of natural herbs such as Kalmegh, Punarnava, Daru Haldi, Manjistha, and Guduchi, positions the brand at the forefront of the wellness journey. These candies serve as effective liver detoxifiers and stress relievers, offering consumers a ‘Dose of Good’ with each bite. Available in two convenient packaging options – a 30-candy box and a 60-candy box – they cater to the growing demand for healthy products.

Simultaneously, R3SET is fortifying its pain-management portfolio with the introduction of the R3SET Ultra Potent Gel. This advanced gel, filled in a strikingly luxurious ceramic jar in 100g packing with twice the effectiveness of its predecessor, reflects R3SET’s commitment to delivering long-term healing solutions for body pain management. Wanting the users to sustainably use and not throw away the jar, the brand will be launching a 300g refill option for the R3SET Ultra Potent Gel, providing customers with a convenient and cost-effective way to replenish their supply, giving back a “Dose of Good” to the planet at the same time.

The brand’s comprehensive pain-reliever product range, including gels, emulsions, sprays and tablets, incorporates natural enhancements and nano-tech formulations, showcasing the fusion of cutting-edge technology with the power of natural painkillers.

R3SET’s commitment extends to environmental stewardship, featuring eco-friendly packaging and collaborations with Forest Stewardship Council (FSC)-certified vendors. The innovative edge of R3SET’s products, rooted in Venus Medicine Research Centre’s extensive research and development, differentiates the brand in the competitive D2C wellness landscape.

R3SET’s strategic shift, bolstered by a transformative rebranding initiative, demonstrates the brand’s dedication to becoming a key player in the holistic healthcare and wellness sector. Along with the refreshed product portfolio, the brand unveiled its new identity, designed to deliver a profound “Dose of Good” at every stage of a consumer’s interaction with the brand, be it through the website, social media, product packaging or the product itself. The rebranding aims to cultivate a community where wellness is seamlessly integrated into daily life.

“R3SET is dedicated to building a community where wellness is an integral part of daily life. Our philosophy is deeply embedded in our new identity, encouraging everyone to pursue a lifestyle centered around health, happiness and holistic wellness” said Mr. Chaudhary.

The post Venus Remedies’ R3SET Takes Strategic Leap into Wellness with Holistic Health Innovations appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.